PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

• ClinicalTrials.gov Identifier: NCT03748706
• Recruitment Status: Completed
• First Posted: November 21, 2018
• Results First Posted: April 1, 2021
• Last Update Posted: July 7, 2021
• Sponsor: Pain Therapeutics
• Collaborator: National Institute on Aging (NIA)
• Information provided by (Responsible Party): Cassava Sciences, Inc. ( Pain Therapeutics )

Study Description

Brief Summary:

This is a Phase 2a, multi-center, open-label study of PTI-125 in mild-to-moderate Alzheimer's disease patients.

Condition or disease	Intervention/treatment	Phase
Alzheimer Disease	Drug: PTI-125, 100 mg tablets	Phase 2

Detailed Description:

This is a Phase 2a, multi-center, open-label study of PTI-125 in mild-to-moderate AD patients, 50-85 years of age. A total of twelve (12) patients will be enrolled into the study. Patients will receive 100 mg b.i.d. of PTI-125. The objectives of this study are to investigate the safety, pharmacokinetics and effect on biomarkers of PTI-125 following 28-day repeat-dose oral administration.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 13 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 2a, Open-label, Multiple Dose, Safety, Pharmacokinetic and Biomarker Study of PTl-125 in Mild-to-moderate Alzheimer's Disease Patients
• Actual Study Start Date: March 7, 2019
• Actual Primary Completion Date: May 8, 2019
• Actual Study Completion Date: May 8, 2019

Arms and Interventions

Arm	Intervention/treatment
Experimental: Simufilam (PTI-125); Simufilam (PTI-125) 100 mg oral tablets administered twice daily (BID)	Drug: PTI-125, 100 mg tablets; PTI-125, 100 mg tablets taken twice a day for 28 days

Outcome Measures

Primary Outcome Measures :

1. Maximum Plasma Concentration (Cmax) [ Time Frame: Study Day 1 and Day 28 at 20, 40, and 60 min and at 1.5, 2, 2.5, 3, 4, 6, 8, 10 and 12 h post-dose ]
   Blood draws will be done to evaluate levels of PTI-125 in the plasma using non-compartmental methods in WinNonlin.
2. Time to Maximum Plasma Concentration (Tmax) [ Time Frame: Study Day 1 and Day 28 at 20, 40, and 60 min and at 1.5, 2, 2.5, 3, 4, 6, 8, 10 and 12 h post-dose ]
   Levels of PTI-125 will be assessed to determine how long it takes to reach the Cmax
3. Last Quantifiable Plasma Concentration (Clast) [ Time Frame: Study Day 1 and Day 28 at 20, 40, and 60 min and at 1.5, 2, 2.5, 3, 4, 6, 8, 10 and 12 h post-dose ]
   Levels of PTI-125 will be assessed to determine the last time point where PTI-125 can be detected.
4. Time to Last Quantifiable Plasma Concentration (Tlast) [ Time Frame: Study Day 1 and Day 28 at 20, 40, and 60 min and at 1.5, 2, 2.5, 3, 4, 6, 8, 10 and 12 h post-dose ]
   Levels of PTI-125 will be assessed to determine the elapsed time to where PTI-125 can last be detected in the plasma.
5. Area Under the Curve (AUClast) [ Time Frame: Study Day 1 and Day 28 at 20, 40, and 60 min and at 1.5, 2, 2.5, 3, 4, 6, 8, 10 and 12 h post-dose ]
   AUC for PTI-125 plasma concentration from time zero to the last quantifiable plasma concentration.
6. Plasma Half-life (T1/2) [ Time Frame: Study Day 1 and Day 28 at 20, 40, and 60 min and at 1.5, 2, 2.5, 3, 4, 6, 8, 10 and 12 h post-dose ]
   Assessment of the half-life in plasma of PTI-125

Secondary Outcome Measures :

1. SavaDx (Biomarker) [ Time Frame: Study Day 1 and Day 28 ]
   Blood samples will be tested for the complementary diagnostic/biomarker for Alzheimer's disease.
2. CSF Biomarkers [ Time Frame: Change from Baseline to Day 28 ]
   A cerebrospinal fluid sample collection will be performed for Aβ42, tau, YKL40 and other potential CSF biomarkers

Eligibility Criteria

• Ages Eligible for Study: 50 Years to 85 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Ages >= 50 and <= 85 years
• Informed consent form (ICF) signed by the subject or legally acceptable representative.
• Clinical diagnosis of dementia due to possible or probable Alzheimer's disease
• Mini-Mental State Examination score >= 16 and <= 24 at screening
• If female, postmenopausal for at least 1 year
• Patient living at home, senior residential setting, or an institutional setting without the need for continuous (i.e. 24-hour) nursing care
• General health status acceptable for participation in the study
• Fluency (oral and written) in English or Spanish
• If receiving memantine, rivastigmine, galantamine or an AChEI, receiving a stable dose for at least 3 months (90 days) before screening and with continuous dosing for at least 3 months. If receiving donepezil, receiving any dose lower than 23 mg once daily.
• The patient is a non-smoker for at least 12 months.
• The patient or legal representative must agree to comply with the drawing of blood samples and with a lumbar puncture and the drawing of cerebrospinal fluid samples.
• The patient has a ratio of total tau/Abeta42 in cerebrospinal fluid >= 0.30.
• Patient has a caregiver or legal representative responsible for administering the drug and recording the time.

Exclusion Criteria:

• Exposure to an experimental drug, experimental biologic or experimental medical device within the longer of 5 half-lives or 3 months before screening
• Residence in a skilled nursing facility
• Clinically significant laboratory test results
• Clinically significant untreated hypothyroidism (if treated, thyroid-stimulating hormone level and thyroid supplementation dose must be stable for at least 6 months before screening)
• Insufficiently controlled diabetes mellitus or requiring insulin
• Renal insufficiency (serum creatinine >2.0 mg/dL)
• Malignant tumor within 3 years before screening (except squamous and basal cell carcinoma or cervical carcinoma in situ or localized prostate cancer or localized stage 1 bladder cancer)
• History of ischemic colitis or ischemic enterocolitis
• Unstable medical condition that is clinically significant in the judgment of the investigator
• Alanine transaminase (ALT) or aspartate transaminase (AST) >2 times the upper limit of normal or total bilirubin greater than the upper limit of normal.
• History of myocardial infarction or unstable angina within 6 months before screening
• History of more than 1 myocardial infarction within 5 years before screening
• Clinically significant cardiac arrhythmia (including atrial fibrillation), cardiomyopathy, or cardiac conduction defect (patients with a pacemaker are acceptable)
• Symptomatic hypotension, or uncontrolled hypertension
• Clinically significant abnormality on screening electrocardiogram (ECG), including but not necessarily limited to a confirmed corrected QT value >= 450 msec for males or >= 470 msec for females.
• Stroke within 18 months before screening, or history of a stroke concomitant with onset of dementia
• History of brain tumor or other clinically significant space-occupying lesion on CT or MRI
• Head trauma with clinically significant loss of consciousness within 12 months before screening or concurrent with the onset of dementia
• Onset of dementia secondary to cardiac arrest, surgery with general anesthesia, or resuscitation
• Specific degenerative CNS disease diagnosis other than Alzheimer's disease (eg, Huntington's disease, Creutzfeld-Jacob disease, Down's syndrome, Frontotemporal Dementia, Parkinson's disease)
• Wernicke's encephalopathy
• Active acute or chronic Central Nervous System infection
• Donepezil 23 mg or greater quaque die currently or within 3 months prior to enrollment in the study
• Discontinued AChEI < 30 days prior to enrollment in the study
• Antipsychotics; low doses are allowed only if given for sleep disturbances, agitation and/or aggression, and only if the subject has received a stable dose for at least 3 months before enrollment in the study
• Tricyclic antidepressants and monoamine oxidase inhibitors; all other antidepressants are allowed only if the subject has received a stable dose for at least 3 months before enrollment in the study
• Anxiolytics or sedative-hypnotics, including barbiturates (unless given in low doses for benign tremor); low doses of benzodiazepines and zolpidem are allowed only if given for insomnia/sleep disturbance, and only if the subject has received a stable dose for at least 3 months before enrollment in the study
• Peripherally acting drugs with effects on cholinergic transmission
• Immunosuppressants, including systemic corticosteroids, if taken in clinically immunosuppressive doses (Steroid use for allergy or other inflammation is permitted.)
• Antiepileptic medications if taken for control of seizures
• Chronic intake of opioid-containing analgesics
• Sedating H1 antihistamines
• Nicotine therapy (all dosage forms including a patch), varenicline (Chantix), or similar therapeutic agent within 30 days before screening
• Clinically significant illness within 30 days of enrollment
• History of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease
• Positive serum hepatitis B surface antigen (HBsAg) or positive hepatitis C virus (HCV) antibody test at screening
• Positive HIV test at screening
• Loss of a significant volume of blood (> 450 mL) within 4 weeks prior to the study
• Metformin or cimetidine.

Contacts and Locations

Locations

United States, Texas

Insite Clinical Research

DeSoto, Texas, United States, 75115

Clinical Trials of Texas

San Antonio, Texas, United States, 78229

Sponsors and Collaborators

Pain Therapeutics

National Institute on Aging (NIA)

Investigators

• Study Director: Lindsay Burns, PhD; Cassava Sciences, Inc.

  Study Documents (Full-Text)

Documents provided by Cassava Sciences, Inc. ( Pain Therapeutics ):

Study Protocol and Informed Consent Form  [PDF] February 5, 2019

Statistical Analysis Plan  [PDF] March 16, 2020

More Information

Additional Information:

Cassava Sciences company website 

Publications of Results:

Wang HY, Pei Z, Lee KC, Lopez-Brignoni E, Nikolov B, Crowley CA, Marsman MR, Barbier R, Friedmann N, Burns LH. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients. J Prev Alzheimers Dis. 2020;7(4):256-264. doi: 10.14283/jpad.2020.6.

Other Publications:

Wang HY, Lee KC, Pei Z, Khan A, Bakshi K, Burns LH. PTI-125 binds and reverses an altered conformation of filamin A to reduce Alzheimer's disease pathogenesis. Neurobiol Aging. 2017 Jul;55:99-114. doi: 10.1016/j.neurobiolaging.2017.03.016. Epub 2017 Mar 31.

Wang HY, Bakshi K, Frankfurt M, Stucky A, Goberdhan M, Shah SM, Burns LH. Reducing amyloid-related Alzheimer's disease pathogenesis by a small molecule targeting filamin A. J Neurosci. 2012 Jul 18;32(29):9773-84. doi: 10.1523/JNEUROSCI.0354-12.2012. Erratum In: J Neurosci. 2021 Dec 15;41(50):10405. J Neurosci. 2022 Jan 19;42(3):529.

• Responsible Party: Pain Therapeutics
• ClinicalTrials.gov Identifier: NCT03748706
• Other Study ID Numbers: PTI-125-03; R44AG060878 ( U.S. NIH Grant/Contract )
• First Posted: November 21, 2018
• Results First Posted: April 1, 2021
• Last Update Posted: July 7, 2021
• Last Verified: June 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Alzheimer Disease; Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders